Introduction
============

COPD is a common disease worldwide. Both COPD and aging lead to progressive deterioration in physical activity and lung function. Physical inactivity impacts the prognosis and can cause symptoms that may induce a vicious circle in advanced-age patients with COPD.[@b1-copd-14-129] In fact, functional constipation is one such symptom associated with physical inactivity,[@b2-copd-14-129] and patients with COPD who develop severe exacerbation requiring hospitalization are reportedly likely to be aged ≥75 years.[@b3-copd-14-129]

Patients with COPD are prone to acute worsening in their condition; this is known as COPD exacerbation. Because COPD is not curable, pharmacotherapy for COPD primarily aims to improve symptoms and prevent exacerbations. The use of long-acting bronchodilators such as long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-agonists (LABAs) either alone or in combination is the first-line treatment for symptomatic COPD; such therapy is also effective for the prevention of COPD exacerbation.[@b4-copd-14-129],[@b5-copd-14-129] However, bronchodilators, particularly LAMAs, may potentially cause anticholinergic adverse events such as constipation in patients with COPD.[@b6-copd-14-129]

Recent studies have focused on the contribution of the gastrointestinal tract in patients with COPD in both the stable state[@b7-copd-14-129] and during exacerbation.[@b8-copd-14-129] Dai-kenchu-to (TU-100, Da Jian Zhong Tang in Chinese), the most frequently prescribed traditional Japanese herbal Kampo medicine, activates intestinal motility.[@b9-copd-14-129],[@b10-copd-14-129] Dai-kenchu-to consists of natural food ingredients: Zingiberis processum rhizome, Ginseng radix, Zanthoxyli piperiti pericarpium (Chinese Da Jian Zhong Tang contains Zanthoxyli pericarpium instead), and Saccharum grano rum.[@b11-copd-14-129] Dai-kenchu-to has been widely prescribed in patients with gastrointestinal disorders such as postoperative paralytic ileus[@b9-copd-14-129],[@b12-copd-14-129]--[@b15-copd-14-129] and chronic constipation[@b16-copd-14-129],[@b17-copd-14-129] and is referred to in the chronic constipation guideline in Japan. Dai-kenchu-to is different from laxatives in that it is taken more regularly than laxatives, which are sometimes prescribed for single use or for a short term. Advanced-age patients with COPD constitutively experiencing abdominal bloating and/or chronic constipation are likely to be treated with Dai-kenchu-to. Bridging the concept of Oriental herbal medicine (ie, modulation of the respiratory system through the maintenance of digestive function) to modern medicine is desired.

The objective of this study was to evaluate the effect of Dai-kenchu-to on COPD exacerbation in patients of advanced age with the intention to provide evidence regarding supportive therapy for advanced-age patients with COPD.

Patients and methods
====================

Data source
-----------

For this retrospective cohort study, we used the Japanese Diagnosis Procedure Combination (DPC) database. The DPC database with outpatient data includes discharge abstracts and administrative claims data from around 250 acute-care hospitals in Japan. The DPC database includes the following data: age, sex, body height and weight (body mass index), primary and comorbid diagnosis, Barthel index at admission and discharge, smoking history, A-DROP (Age-Dehydration-Respiratory failure-Orientation disturbance-blood Pressure) score, Hugh--Jones score, information regarding operative procedures and anesthesia, discharge status, medications and treatment in both inpatient and outpatient settings, and dates of admission and discharge. All analyses and data reporting in this study complied with the Strengthening the Reporting of Observational Studies in Epidemiology guideline. This study was approved by the Institutional Review Board of The University of Tokyo, which waived the requirement for informed patient consent because of the anonymous nature of the data.

Patient selection
-----------------

We extracted inpatient data of patients aged ≥75 years who were hospitalized for COPD exacerbation, and then extracted the outpatient data of these patients from July 2010 to March 2016. Patients with COPD were identified with the following ICD-10 codes: J41, J42, J43, J440, J441, and J449. Hospitalized patients with COPD exacerbation were identified with the following ICD-10 codes: J10, J11, J13, J14, J15, J16, J18, J20, J21, J22, J46, J170, J171, J178, J440, J441, J851, J12, A481, B012, B052, and B250. The Dai-kenchu-to group was defined as patients who received Dai-kenchu-to before or during hospitalization for COPD exacerbation. The control group comprised patients who did not receive Dai-kenchu-to throughout the observation period. Patients with no outpatient data before hospitalization, after hospitalization, or both before and after hospitalization and patients who died during the initial hospitalization for COPD exacerbation were excluded. Patients for whom Dai-kenchu-to was prescribed only after discharge from the initial hospitalization for COPD exacerbation were also excluded.

Outcomes
--------

The outcome was re-hospitalization for COPD exacerbation or death.

Statistical analyses
--------------------

We used the standardized difference to compare baseline characteristics, including comorbidities and treatments, between the Dai-kenchu-to group and the control group. Continuous variables are reported as mean ± SD. Dichotomous parameters and categorical variables are reported as frequency. Missing data for categorical variables are categorized as missing. The baseline characteristics were sex, fiscal year, season at admission, residential region, Hugh--Jones dyspnea score at admission, activities of daily living scores at admission and discharge (Barthel index), age, body mass index, and frequency of COPD exacerbations before hospitalization. COPD exacerbation before hospitalization was defined by episodes in which corticosteroids and/or antibiotics and/or anti-flu medicines were prescribed ([Table S1](#SD1-copd-14-129){ref-type="supplementary-material"}). Comorbidities ([Table S2](#SD2-copd-14-129){ref-type="supplementary-material"}) and treatments assessed were lung cancer, other malignancy, interstitial pneumonia, bronchial asthma, bronchiectasis, bacterial lower respiratory tract infection, *Mycobacterium* infection, mycosis, cor pulmonale, congestive heart failure, ischemic heart disease, tachycardia, autoimmune disease, stroke, liver dysfunction, renal failure, gastroesophageal reflux disease, constipation and/or ileus, prostate hypertrophy, home ventilator support, home oxygen therapy, inhaled corticosteroids before hospitalization, long-acting musca-rinic receptor antagonists before hospitalization, LABA before hospitalization, other medications for COPD before hospitalization, ambulance transport, corticosteroid therapy during hospitalization, mechanical ventilation during hospi-talization, nasal tube feeding during hospitalization, surgery under general anesthesia during hospitalization, discharge to home, and length of stay. ICD-10 codes for comorbidities are shown in [Table S2](#SD2-copd-14-129){ref-type="supplementary-material"}. An absolute standardized difference of \>10% was considered to indicate significant imbalance.

We performed propensity score analysis to account for the differences in baseline characteristics between the two groups. The propensity scores were estimated using a multi-variable logistic regression model that included the aforementioned covariates as the dependent variables.[@b18-copd-14-129] We performed 1-to-4 matching between the Dai-kenchu-to group and the control group. Kaplan--Meier curves were drawn, and a log-rank test was then used to compare the survival curves of the two groups. A Cox proportional hazards model was used to estimate the HR of re-hospitalization for COPD exacerbation or death. Patients who were neither re-hospitalized for COPD exacerbation nor died during the observation period were censored at the date of the last visit to each hospital.

All data were analyzed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA) and STATA software version 14.1 (StataCorp LP, College Station, TX, USA). Values of *P*\<0.05 were considered to indicate statistical significance.

Subgroup analyses
-----------------

We also performed subgroup analyses of patients with and without LAMA therapy. Patients with COPD who received either a LAMA alone or a LAMA in combination with a LABA (LABA/LAMA) before hospitalization may have been more likely to have worse symptoms and lower lung function with a higher risk of frailty and subsequent reduced gastrointestinal motility; therefore, we considered that they may benefit more from Dai-kenchu-to than patients without LAMA or LABA/LAMA therapy. Kaplan--Meier curves, a log-rank test, and a Cox proportional hazards model were used to compare the two groups.

Results
=======

We identified 12,691 patients aged ≥75 years who were hospitalized for COPD exacerbation and had outpatient data before and after hospitalization for COPD exacerbation. Among them, Dai-kenchu-to was prescribed to 518 patients before or during hospitalization for COPD exacerbation ([Figure 1](#f1-copd-14-129){ref-type="fig"}).

[Table 1](#t1-copd-14-129){ref-type="table"} shows the baseline characteristics in the Dai-kenchu-to group and the control group. The number of patients in the Dai-kenchu-to group and control group after 1-to-4 propensity score matching was 477 and 1,908, respectively. Comorbidities during the initial hospitalization and treatments for COPD before and during hospitalization are shown in [Table 2](#t2-copd-14-129){ref-type="table"}. Malignancies other than lung cancer and constipation and/or ileus were more common in the Dai-ken-chu-to group than the control group. Medications for COPD, including LAMAs, were more frequently administered in the Dai-kenchu-to group. After 1-to-4 propensity score matching, the distributions of most covariates were well balanced between the two groups.

The median observation period after discharge from the first hospitalization for COPD exacerbation was 303 days (IQR, 104--594 days) in the Dai-kenchu-to group and 308 days (IQR, 100--678 days) in the control group. During the observation period, 127 (24.5%) and 3,379 (27.8%) patients were either re-hospitalized for COPD exacerbation or died in the Dai-kenchu-to group and control group, respectively.

Propensity scores were calculated using all the variables listed in [Tables 1](#t1-copd-14-129){ref-type="table"} and [2](#t2-copd-14-129){ref-type="table"}. After propensity score matching, the numbers of patients who were either re-hospitalized for COPD exacerbation or died during the observational period were 116 (24.3%) and 536 (28.2%) in the Dai-kenchu-to group and the control group, respectively.

[Figure 2](#f2-copd-14-129){ref-type="fig"} and [Table 3](#t3-copd-14-129){ref-type="table"} show the results of the survival analyses after 1-to-4 propensity score matching. The log-rank test showed a statistically significant difference (*P*=0.050) with better survival in the Dai-kenchu-to group ([Figure 2A](#f2-copd-14-129){ref-type="fig"}). In the analyses using the Cox proportional hazard model, the Dai-kenchu-to group showed a significantly reduced risk of re-hospitalization or death in the 1-to-4 propensity score analysis (HR, 0.82; 95% CI, 0.67--0.99; *P*=0.050), as shown in [Table 3](#t3-copd-14-129){ref-type="table"}.

In the subgroup analysis of patients with LAMA therapy, a significant difference in re-hospitalization or death was observed between the two groups ([Figure 2B](#f2-copd-14-129){ref-type="fig"}). Among patients without LAMA therapy, no significant difference in re-hospitalization or death was observed between the two groups ([Figure 2C](#f2-copd-14-129){ref-type="fig"}).

Discussion
==========

This study showed a reduced risk of re-hospitalization for COPD exacerbation or death in the Dai-kenchu-to group vs control group among ≥75-year-old patients with COPD, using 1-to-4 propensity score matching. The subgroup analysis of patients without LAMA therapy showed no significant difference in the outcome between the Dai-kenchu-to users and non-users. Our findings indicate that Dai-kenchu-to may reduce the risk of severe COPD exacerbation requiring hospitalization, particularly in advanced-age patients with COPD, possibly by improving treatment adherence in LAMA users. Our study is the first to evaluate the relationship between Dai-kenchu-to (TU-100) and COPD. We also attempted to provide a bridge between the concept of traditional Oriental herbal medicine and modern medicine.

We were not able to clearly show the mechanisms that explain our findings in the present study. Despite numerous studies demonstrating the effect and mechanism[@b9-copd-14-129]--[@b17-copd-14-129] of Dai-kenchu-to in the gut, no studies have yet evaluated the additional benefits of Dai-kenchu-to in the organs outside the digestive system. However, there are several possible explanations for why Dai-kenchu-to was preferable in advanced-age patients with COPD, especially in LAMA users. Improved gut motility is a major effect of Dai-kenchu-to, and this can be a plausible mechanism for reducing exacerbation in advanced-age patients with COPD. In general, patients of advanced age are susceptible to abdominal bloating and/or constipation.[@b19-copd-14-129]--[@b21-copd-14-129] Patients aged \>75 years using LAMAs are likely to have an advanced stage of COPD with a higher risk of frailty and reduced gastrointestinal motility than those not using LAMAs, which may explain their response to the treatment with Dai-kenchu-to. Moreover, such patients are vulnerable to adverse drug reactions,[@b22-copd-14-129] which may also be true of LAMAs. Dai-kenchu-to may show improved patient adherence to long-acting bronchodilators, particularly advanced-age patients with COPD experiencing abdominal bloating and/or constipation, resulting in a lower risk of re-hospitalization.

Furthermore, because the thoracic lumen shares the diaphragm with the abdominal lumen, the diaphragmatic response to abdominal loading inevitably affects the lung function, particularly in advanced-age patients with COPD whose costal wall is unlikely to further expand horizontally to compensate for the limitation in vertical extension of the lung.[@b23-copd-14-129] In fact, diaphragmatic motion during tidal breathing is reportedly greater in patients with than without COPD, suggesting a pivotal role of diaphragmatic motion in compensation for breathlessness.[@b24-copd-14-129] Abdominal bloating and/or constipation may interfere with diaphragmatic motion and may aggravate symptoms in advanced-age patients with COPD, resulting in reduced physical activity and thereby increasing the risk of COPD exacerbation.[@b25-copd-14-129] Further studies are required to assess whether the effect of Dai-kenchu-to simply relies on the improvement of gut motility.

Intestinal hyperpermeability following splanchnic hypoxia, possibly caused by blood flow redistribution, may lead to increased bacterial translocation in patients with COPD.[@b7-copd-14-129],[@b8-copd-14-129] Dai-kenchu-to in both animals[@b26-copd-14-129] and humans[@b27-copd-14-129] increases intestinal blood flow. A protective effect of Dai-kenchu-to against bacterial translocation has been shown in rats.[@b28-copd-14-129]--[@b30-copd-14-129] Dai-kenchu-to may have reduced the risk of COPD exacerbation in older patients in the present study by preserving intestinal blood flow and preventing bacterial translocation.

In addition, disruption of the microbiome in patients with lung disease, including COPD, has been reviewed,[@b31-copd-14-129] and the modulatory effect of Dai-kenchu-to on the microbiome has been studied.[@b32-copd-14-129],[@b33-copd-14-129] In one study, Dai-kenchu-to preserved the diversity of the microbiome in stressed mice. In another study, it reshaped the proportion of the microbiome with increased short-chain fatty acids in rats. The increased short-chain fatty acids reportedly suppressed inflammation in the lungs and were protective in a mouse model of elastase-induced emphysema.[@b34-copd-14-129] Moreover, short-chain fatty acids have been implicated in the immune response[@b35-copd-14-129] and non-eosinophilic hyperresponsiveness in the airway.[@b36-copd-14-129] The modulatory effect of Dai-kenchu-to on the microbiome in the gut may serve as a basis for further exploration of the mechanism of Dai-kenchu-to in advanced-age patients with COPD.

The capability of Dai-kenchu-to to activate transient receptor potential ankyrin (TRPA) channels or transient receptor potential vanilloid (TRPV) channels is also of interest.[@b11-copd-14-129] Activation of TRPA and TRPV channels on vagal sensory nerves in the airways initiates the cough reflex, which is considered to be a therapeutic target when excessive in disease states.[@b37-copd-14-129] The protective effect of cough (ie, clearing harmful particles from the airway) is also acknowledged, particularly in stable states. However, whether Dai-kenchu-to can activate TRPA or TRPV channels in the airway has not been demonstrated. Therefore, further in vivo studies are required.

Several limitations of this study should be acknowledged. First, patients who switched hospitals during the study period and patients whose outpatient care hospital differed from the hospital for hospitalization were not captured. This may be a potential source of confounding. Second, the database does not contain data for each patient's pulmonary function tests and symptoms. We, therefore, evaluated medications for COPD in the stable states (before hospitalization) as a surrogate for pulmonary function tests and symptoms. Third, factors such as the current smoking status and actual baseline physical activity, both of which may affect the outcomes, were not recorded in the DPC database. Fourth, in our propensity score-matching analysis, some variables such as residential regions, Hugh--Jones dyspnea, and activities of daily living at discharge were not well balanced. However, we performed a reanalysis with these three variables included as independent variables in the Cox regression model after 1-to-4 propensity score matching and obtained a similar result (HR, 0.81; 95% CI, 0.66--0.99; *P*=0.039).

Conclusion
==========

Our study suggests that Dai-kenchu-to may reduce the risk of re-hospitalization for COPD exacerbation, most likely by improving the adherence to LAMAs in advanced-age patients with COPD. Prospective studies to confirm our findings and to elucidate the mechanisms of the protective effect of Dai-kenchu-to in advanced-age patients with COPD are needed.

Supplementary materials
=======================

###### 

List of drugs used to treat COPD and drugs used to define COPD exacerbation in outpatient settings

  Medications for COPD                   
  -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ICS                                    Beclomethasone, fluticasone, budesonide, ciclesonide, mometasone
  LAMA                                   Titropium, glycopyrronium, umeclidinium
  LABA                                   Salmeterol, formoterol, indacaterol, vilanterol, tulobuterol
  Other medications for COPD             Theophylline, acetylcysteine, ambroxol, carbocisteine, fudosteine, bromhexine, salbutamol, fenoterol, procaterol, ipratropium, oxitropium
  **Drugs used for COPD exacerbation**   
  Systemic corticosteroids               Dexamethasone, paramethasone, prednisolone, methylprednisolone, betamethasone, triamcinolone, hydrocortisone
  Antibiotics                            Benzylpenicillin, aspoxicillin, amoxicillin, ampicillin, amoxicillin/clavulanate, bacampicilin, cinoxacin piperacillin, pivemecillinam, sulbactam/ampicillin, tazobactam/piperacillin, abpc-mcipc, cefroxadine, cefaclor, cefalex, cefalotin, cefazolin, cefuroxime, cefotiam, cefmetazol, cefotiam, flomoxef, cefminox, cefodizime, latamoxef, sulbactam/ cefoperazone, cefotaxime, cefoperazone, cefixime, ceftibuten, cefbuperazone, cefcapene pivoxil, cefteram pivoxil, cefpodoxime proxetil, cefteram pivoxil cefpirome, cefmenoxime, csfditoren, ceftazidime, ceftriaxone, cefozopran, cefepime, ceftizoxime, telithromycin, clindamycin, amikacin isepamicin, gentamicin, tobramycin, didekacin, aztreonam, erythromycin, clarithromycin, azithromycin, josamycin, roxithromycin, aztreonam, tosufloxacin, ofloxacin, garenoxacin, levofloxacin, sitafloxacin, ciprofloxacin, tosufloxacin, norfloxacin, pazufloxacin, prulifloxacin, moxifloxacin, lomefloxcin, faropenem, biapenem, tebipenem pivoxil, panipenem/betamipron, imipenem/cilastatin, doripenem, meropenem
  Anti-flu medicine                      Oseltamivir, zanamivir, peramivir, laninamivir

**Abbreviations:** ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic receptor antagonist.

###### 

ICD-10 codes used to identify comorbidities

  Comorbidity                                   ICD-10 codes
  --------------------------------------------- -------------------------------------------------------------------------------------------
  Lung cancer                                   C34
  Other malignancy                              C00--26, C30--33, C37--41, C43--58, C60--76
  Interstitial pneumonia                        B221, J701, J704, J841, J848, J849, J990, J991, M321, M330, M331, M332, M351
  Bronchial asthma                              J45, J46
  Bronchiectasis                                J40, J41, J42, J47
  Bacterial lower respiratory tract infection   A481, J100, J110, J13--16, J170, J178, J18, J85, J86
  *Mycobacterium* infection                     A150--154, A156--159, A161--162, A165, A168--169, A19, A310, A319
  Mycotic infection                             A420, A43, B37, B380--382, B390--392, B400--402, B410, B420, B440, B441, B449, B460, J172
  Cor pulmonale                                 I27
  Congestive heart failure                      E059, I46, I50, I099, I110
  Ischemic heart disease                        I20--25
  Tachycardia                                   I47--49, R000, T818
  Autoimmune disease                            M05, M06, M08, M30--35
  Stroke                                        I60--64
  Liver dysfunction                             B89, B181, B182, B659, B661, K702, K703, K72, K74, K761, K762, K763, K766, K767
  Renal failure                                 E102, E112, E142, I120, N17--19
  GERD                                          K21
  Constipation and/or ileus                     K56, K590
  Prostate hypertrophy                          N40

**Abbreviation:** GERD, gastroesophageal reflux disease.
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![Flow diagram of patient selection.](copd-14-129Fig1){#f1-copd-14-129}

![Kaplan--Meier survival curves of patients with COPD with or without Dai-kenchu-to after hospitalization for COPD exacerbation in the 1-to-4 propensity score-matched population. (**A**) Results for patients aged ≥75 years. (**B**) Results for patients with LAMA therapy. (**C**) Results for patients without LAMA therapy before hospitalization. The Kaplan--Meier curves were compared with a log-rank test. A *P*-value of \<0.05 indicated statistical significance.\
**Abbreviation:** LAMA, long-acting muscarinic receptor antagonist.](copd-14-129Fig2){#f2-copd-14-129}

###### 

Baseline characteristics of patients with COPD aged ≥75 years with and without Dai-kenchu-to, before and after 1-to-4 propensity score matching

  Characteristic (categorical)                      All patients   After 1-to-4 matching                                                                          
  ------------------------------------------------- -------------- ----------------------- ---------- -------- ---------- ---------- -------- ---------- -------- ----------
                                                                                                                                                                  
  Sex (male)                                        80.1           85.9                    -0.134     86.6     85.5       0.032                                   
  Fiscal year                                                                                                                                                     
   2010                                             12.3           8.7                     -0.125     7.4      8.2        0.027                                   
   2011                                             16.6           9.9                     -0.213     10.7     9.2        -0.051                                  
   2012                                             17.8           16.4                    -0.031     16.3     16.6       0.007                                   
   2013                                             17.9           17.8                    0.005      16.0     18.2       0.058                                   
   2014                                             19.4           24.7                    0.108      25.1     24.1       -0.023                                  
   2015                                             16.0           22.6                    0.185      24.4     23.7       -0.016                                  
  Seasons at admission                                                                                                                                            
   Spring                                           24.4           25.7                    0.034      24.7     25.8       0.035                                   
   Summer                                           23.0           22.8                    -0.016     24.0     22.2       -0.042                                  
   Autumn                                           23.3           22.4                    -0.031     24.2     22.0       -0.052                                  
   Winter                                           29.3           29.2                    0.010      27.5     30.0       0.054                                   
  Residential regions                                                                                                                                             
  Hokkaido and Tohoku                               9.0            8.5                     -0.009     13.1     8.8        -0.136                                  
   Kanto                                            28.7           37.5                    0.197      31.5     36.9       0.114                                   
   Chubu                                            20.3           18.9                    -0.022     20.6     19.7       -0.022                                  
   Kansai                                           14.8           14.5                    -0.056     14.3     12.8       -0.043                                  
  Chugoku, Shikoku, Kyushu, and Okinawa             27.3           20.7                    -0.142     20.6     21.8       0.029                                   
  Hugh--Jones dyspnea score at admission                                                                                                                          
   1                                                10.0           12.2                    0.081      9.5      13.0       0.111                                   
   2--3                                             31.5           26.5                    -0.111     31.3     27.0       -0.095                                  
   4--5                                             46.9           46.9                    0.008      46.7     46.8       0.002                                   
   Missing                                          11.7           14.5                    0.063      12.5     13.2       0.020                                   
  ADL at admission (Barthel index)                                                                                                                                
   95--100                                          26.5           30.5                    0.067      25.7     28.5       0.064                                   
   55--90                                           21.6           18.5                    -0.078     21.8     19.1       -0.066                                  
   0--50                                            35.0           35.1                    0.006      35.9     36.5       0.012                                   
   Missing                                          16.9           15.8                    -0.003     16.7     15.9       -0.020                                  
  ADL at discharge (Barthel index)                                                                                                                                
   95--100                                          13.8           17.8                    0.078      11.7     15.7       0.118                                   
   55--90                                           20.4           18.9                    -0.023     19.9     19.5       -0.009                                  
   0--50                                            55.7           51.5                    -0.080     57.3     53.3       -0.082                                  
   Missing                                          10.0           11.8                    0.071      11.1     11.5       0.013                                   
                                                                                                                                                                  
  **Characteristic (numerical)**                    **Mean**       **SD**                  **Mean**   **SD**   **s.d.**   **Mean**   **SD**   **Mean**   **SD**   **s.d.**
                                                                                                                                                                  
  Age (years)                                       82.0           4.8                     82.2       4.9      0.025      82.1       4.8      82.1       4.8      -0.000
  Body mass index (kg/m^2^)                         20.6           3.7                     20.2       3.8      -0.130     20.2       3.6      20.2       3.7      -0.019
  Frequency of COPD exacerbation before admission   5.4            12.1                    7.9        13.3     0.218      8.1        15.5     8.3        13.7     -0.002

**Abbreviations:** ADL, activities of daily living; s.d., standardized difference.

###### 

Comorbidities during hospitalization and treatments for COPD in patients aged ≥75 years with and without Dai-kenchu-to

  Comorbidities                   All patients   After 1-to-4 matching                                                                          
  ------------------------------- -------------- ----------------------- ---------- -------- ---------- ---------- -------- ---------- -------- ----------
                                                                                                                                                
  Lung cancer                     8.2            9.7                     0.055      11.0     10.1       -0.029                                  
  Other malignancy                9.1            22.2                    0.370      22.5     22.9       0.009                                   
  Interstitial pneumonia          5.0            4.8                     -0.001     5.2      5.0        -0.009                                  
  Bronchial asthma                25.5           25.3                    -0.000     27.3     25.6       -0.038                                  
  Bronchiectasis                  23.9           24.3                    0.013      25.0     24.3       -0.016                                  
  Bacterial lower respiratory     85.4           88.0                    0.080      89.0     88.1       -0.030                                  
  tract infection                                                                                                                               
  *Mycobacterium* infection       2.0            1.2                     -0.076     0.6      1.1        0.046                                   
  Mycotic infection               1.4            1.5                     0.038      1.8      1.9        0.008                                   
  Cor pulmonale                   1.0            1.5                     0.047      1.6      1.5        -0.013                                  
  Congestive heart failure        21.3           24.5                    0.093      25.9     25.0       -0.023                                  
  Ischemic heart disease          11.8           11.6                    0.008      11.9     12.4       -0.002                                  
  Tachycardia                     8.6            8.9                     0.017      9.3      9.2        -0.002                                  
  Autoimmune disease              3.4            2.7                     -0.030     3.3      2.9        -0.021                                  
  Stroke                          2.6            1.9                     -0.054     1.6      1.7        0.008                                   
  Liver dysfunction               1.7            1.4                     -0.040     1.4      1.3        -0.009                                  
  Renal failure                   4.7            4.4                     0.003      4.8      4.8        -0.000                                  
  GERD                            14.2           16.2                    0.066      16.9     16.6       -0.010                                  
  Constipation or ileus           11.2           18.9                    0.203      17.6     18.5       0.022                                   
  Prostate hypertrophy            8.7            11.4                    0.100      12.3     11.7       -0.018                                  
  **Treatments**                  **%**          **%**                   **s.d.**   **%**    **%**      **s.d.**                                
  Home ventilatory support        1.2            1.2                     0.009      1.4      1.3        -0.009                                  
  Home oxygen therapy             14.9           18.7                    0.100      17.3     18.7       0.035                                   
  ICS before admission            27.6           34.6                    0.148      34.8     34.8       0.001                                   
  LAMA before admission           30.1           39.2                    0.181      37.9     39.0       0.023                                   
  LABA before admission           39.5           50.0                    0.218      48.9     50.5       0.032                                   
  Other medications for COPD      58.8           70.7                    0.250      71.5     70.9       -0.014                                  
  before admission                                                                                                                              
  Ambulance transport             25.1           25.1                    -0.010     24.0     23.9       -0.001                                  
  Corticosteroids during          35.9           32.4                    -0.075     32.7     32.5       -0.004                                  
  hospitalization                                                                                                                               
  Mechanical ventilation during   4.6            5.0                     -0.004     4.8      4.4        0.018                                   
  hospitalization                                                                                                                               
  Nasal tube feeding during       1.8            3.3                     0.095      2.6      3.1        0.031                                   
  hospitalization                                                                                                                               
  Surgery under general           0.5            0.8                     0.041      0.8      0.8        -0.000                                  
  anesthesia during                                                                                                                             
  hospitalization                                                                                                                               
  Discharge to home               91.7           92.3                    0.046      94.0     93.3       -0.030                                  
                                                                                                                                                
  **Treatment (numerical)**       **Mean**       **SD**                  **Mean**   **SD**   **s.d.**   **Mean**   **SD**   **Mean**   **SD**   **s.d.**
                                                                                                                                                
  Length of stay                  18.9           17.5                    19.6       19.7     0.020      19.3       17.1     19.2       19.3     -0.003

**Abbreviations:** GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic receptor antagonist; s.d., standardized difference.

###### 

HRs of re-hospitalization for COPD exacerbation or death after 1-to-4 propensity score matching in the Dai-kenchu-to group vs control group

  Patients            Number of patients   HR    95% CI   *P-*value    
  ------------------- -------------------- ----- -------- ------------ -------
                                                                       
  All patients        1,908                477   0.82     0.67--0.99   0.050
  Subgroup analyses                                                    
  LAMA users          744                  186   0.73     0.54--0.99   0.045
  LAMA non-users      1,164                291   1.09     0.83--1.43   0.555

**Abbreviation:** LAMA, long-acting muscarinic receptor antagonist.
